AI Analysis
AI-generated analysis. Always verify with the original filing.
Microbot Medical Inc. announced that Emory Healthcare successfully completed robotic peripheral endovascular procedures using the LIBERTY Endovascular Robotic System, including the world's first robotic Prostatic Artery Embolization for BPH and robotic Y-90 radioembolization mapping for liver cancer. This demonstrates system adoption across multiple case types ahead of full market release.
Key Takeaways
1Emory Healthcare completed robotic peripheral endovascular procedures using LIBERTY System on March 26, 2026
2First robotic Prostatic Artery Embolization (PAE) for benign prostatic hyperplasia (BPH) performed at Emory
3First robotic Y-90 radioembolization mapping for liver cancer completed using LIBERTY System
4LIBERTY is the only FDA-cleared single-use remotely operated robotic system for peripheral endovascular procedures
5Limited Market Release of LIBERTY commenced November 2025; Full Market Release planned April 2026
6BPH affects approximately 40 million men in the U.S.